119 related articles for article (PubMed ID: 34901697)
1. Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies.
Ardalan B; Azqueta J; Sleeman D
J Pancreat Cancer; 2021; 7(1):65-70. PubMed ID: 34901697
[No Abstract] [Full Text] [Related]
2. Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS
Kenney C; Kunst T; Webb S; Christina D; Arrowood C; Steinberg SM; Mettu NB; Kim EJ; Rudloff U
Invest New Drugs; 2021 Jun; 39(3):821-828. PubMed ID: 33405090
[TBL] [Abstract][Full Text] [Related]
3. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.
Bournet B; Muscari F; Buscail C; Assenat E; Barthet M; Hammel P; Selves J; Guimbaud R; Cordelier P; Buscail L
Clin Transl Gastroenterol; 2016 Mar; 7(3):e157. PubMed ID: 27010960
[TBL] [Abstract][Full Text] [Related]
4. KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas.
Diehl AC; Hannan LM; Zhen DB; Coveler AL; King G; Cohen SA; Harris WP; Shankaran V; Wong KM; Green S; Ng N; Pillarisetty VG; Sham JG; Park JO; Reddi D; Konnick EQ; Pritchard CC; Baker K; Redman M; Chiorean EG
Oncologist; 2022 Dec; 27(12):1025-1033. PubMed ID: 36124727
[TBL] [Abstract][Full Text] [Related]
5. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.
Visani M; de Biase D; Baccarini P; Fabbri C; Polifemo AM; Zanini N; Pession A; Tallini G
Int J Surg Pathol; 2013 Dec; 21(6):546-52. PubMed ID: 23426962
[TBL] [Abstract][Full Text] [Related]
6. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report.
Ardalan B; Azqueta JI; England J; Eatz TA
Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34667063
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers.
Furugaki K; Iwai T; Kondoh K; Moriya Y; Mori K
Oncol Lett; 2010 Mar; 1(2):231-235. PubMed ID: 22966286
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Zhao D; Li H; Mambetsariev I; Mirzapoiazova T; Chen C; Fricke J; Kulkarni P; Villaflor V; Arvanitis L; Hamilton S; Afkhami M; Pillai R; Armstrong B; Erhunmwunsee L; Massarelli E; Sattler M; Amini A; Salgia R
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230855
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
10. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
Shepherd FA; Domerg C; Hainaut P; Jänne PA; Pignon JP; Graziano S; Douillard JY; Brambilla E; Le Chevalier T; Seymour L; Bourredjem A; Le Teuff G; Pirker R; Filipits M; Rosell R; Kratzke R; Bandarchi B; Ma X; Capelletti M; Soria JC; Tsao MS
J Clin Oncol; 2013 Jun; 31(17):2173-81. PubMed ID: 23630215
[TBL] [Abstract][Full Text] [Related]
11. Amplification of mutant
Pittella-Silva F; Kimura Y; Low SK; Nakamura Y; Motoya M
Mol Clin Oncol; 2021 Sep; 15(3):172. PubMed ID: 34276991
[TBL] [Abstract][Full Text] [Related]
12. Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey.
Park JT; Johnson N; Liu S; Levesque M; Wang YJ; Ho H; Huso D; Maitra A; Parsons MJ; Prescott JD; Leach SD
Oncogene; 2015 May; 34(21):2801-6. PubMed ID: 25065594
[TBL] [Abstract][Full Text] [Related]
13. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
[TBL] [Abstract][Full Text] [Related]
14. Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling.
Pantsar T; Rissanen S; Dauch D; Laitinen T; Vattulainen I; Poso A
PLoS Comput Biol; 2018 Sep; 14(9):e1006458. PubMed ID: 30199525
[TBL] [Abstract][Full Text] [Related]
15. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
16. Impact of
Yousef A; Yousef M; Chowdhury S; Abdilleh K; Knafl M; Edelkamp P; Alfaro-Munoz K; Chacko R; Peterson J; Smaglo BG; Wolff RA; Pant S; Lee MS; Willis J; Overman M; Doss S; Matrisian L; Hurd MW; Snyder R; Katz MHG; Wang H; Maitra A; Shen JP; Zhao D
Res Sq; 2023 Aug; ():. PubMed ID: 37609177
[TBL] [Abstract][Full Text] [Related]
17. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
Yousef A; Yousef M; Chowdhury S; Abdilleh K; Knafl M; Edelkamp P; Alfaro-Munoz K; Chacko R; Peterson J; Smaglo BG; Wolff RA; Pant S; Lee MS; Willis J; Overman M; Doss S; Matrisian L; Hurd MW; Snyder R; Katz MHG; Wang H; Maitra A; Shen JP; Zhao D
NPJ Precis Oncol; 2024 Feb; 8(1):27. PubMed ID: 38310130
[TBL] [Abstract][Full Text] [Related]
18. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
19. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
Wang QJ; Yu Z; Griffith K; Hanada K; Restifo NP; Yang JC
Cancer Immunol Res; 2016 Mar; 4(3):204-14. PubMed ID: 26701267
[TBL] [Abstract][Full Text] [Related]
20. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue.
Ako S; Nouso K; Kinugasa H; Dohi C; Matushita H; Mizukawa S; Muro S; Akimoto Y; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Tsutsumi K; Kato H; Okada H
Pancreatology; 2017; 17(2):285-290. PubMed ID: 28139399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]